Mirati Spies ‘First-In-Class’ Chance For KRAS Inhibitor In Pancreatic Cancer
Adds To Colorectal Cancer Opportunity
While chasing Amgen’s Lumakras in NSCLC, Mirati looks to now have an edge in two other tumor types.
While chasing Amgen’s Lumakras in NSCLC, Mirati looks to now have an edge in two other tumor types.